br b National Institute of Oncology Centre of
b National Institute of Oncology, Centre of Radiotherapy, Rath Gyorgy€ Str. 7-9. 1122, Budapest, Hungary
c Semmelweis University, Department of Oncology, Rath Gyorgy€ Str. 7-9. 1122, Budapest, Hungary
d National Institute of Oncology, Department of Molecular Genetics, Rath Gyorgy€ Str. 7-9. 1122, Budapest, Hungary
e National Institute of Oncology, Department of Oncological Internal Medicine and Clinical Pharmacology, Rath Gyorgy€ Str. 7-9. 1122, Budapest, Hungary
f National Institute of Oncology, Centre of Pathology, Rath Gyorgy€ Str. 7-9. 1122 Budapest, Hungary
g Guy's Hospital, Breast Unit, London, Great Maze Pond, London, SE1 9RT, United Kingdom
h National Institute of Oncology, National Cancer Registry, Rath Gyorgy€ Str. 7-9. 1122, Budapest, Hungary
i Semmelweis University, Second Department of Pathology, Ülloi Str. 93. 1091, Budapest, Hungary
Received in revised form
Available online xxx
Very young breast cancer patient
Young breast cancer patient
Background: Breast cancer diagnosed in very young women (VYWBC; 35 years) and young women (YWBC; 36e45 years) tends to be heterogeneous. The current study aimed to compare the clinico-pathological characteristics and long-term clinical outcomes between YWBC and VYWBC subgroups.
Patients and methods: The institutional prospectively led database was retrospectively analysed from 2000 to 2014 at the National Institute of Oncology, Hungary. A total of 297 patients were assigned to the VYWBC group, and 301 patients were assigned to the YWBC group. Results: The median follow-up period was 69 months for the VYWBC group and 79 months for the YWBC group. Significant differences were observed based on breast cancer subtype. The proportion of Triple-negative and ER-negative patients was higher in the VYWBC group than in the YWBC group
(P ¼ 0.00008). The incidence of distant Epoprostenol was significantly higher in the VYWBC group (P ¼ 0.01). Significant differences in the frequency of chemotherapy (P ¼ 0.049) and endocrine therapy (P ¼ 0.037) were observed between the two groups. The YWBC group exhibited significantly better overall survival (OS) and disease-free survival (DFS) rates than did the VYWBC group (P ¼ 0.00005 and P ¼ 0.00004, respectively).
Conclusion: Breast cancers in VYWBC are biologically different from those in YWBC and tend to be more aggressive. Younger age was associated with worse OS and DFS. Young women with breast cancer should be subgrouped into VYWBC and YWBC populations, and these subgroups should be targeted by specialized clinical trials and further investigations.
© 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Breast cancer in young age has gained increasing attention since
the 1st International Consensus Conference for Breast Cancer in Young Women (BCY1) took place in November 2012 in Dublin, Ireland, organized by the European School of Oncology (ESO) . The 2ndconference (BCY2) took place in November 2014 in Dublin, Ireland, and the BCY3 took place in November 2016 in Lugano, Switzerland [2,3]. Consensus recommendations for the manage-ment of breast cancer in young women were developed, and areas r> 0748-7983/© 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Please cite Archeae article as: Szollar A et al., A long-term retrospective comparative study of the oncological outcomes of 598 very young ( 35 years) and young (36e45 years) breast cancer patients, European Journal of Surgical Oncology, https://doi.org/10.1016/j.ejso.2019.06.007